Phathom Pharmaceuticals, is a US biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. Takeda has granted a license to Phathom for the development and exclusive commercialization rights to vonoprazan in the United States, Europe and Canada. Vonoprazan is a novel, orally active potassium competitive acid blocker (P-CAB) discovered and developed by Takeda and marketed by both Takeda and Otsuka in Japan since 2015. P-CABs are a class of drug that competitively block the potassium-binding site of gastric hydrogen potassium ATPase (also known as the proton pump). Abingworth partners Shelley Chu and Andrew Sinclair are observers on the board.

LocationMenlo Park, CA, USA
CEODavid Socks